OPUS GENETICS INC. - COMMON STOCK

Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol®

05 Mar 2021 07:44:07 By Nasdaq GlobeNewswire

Ocuphire to Participate in March Investor Conferences

04 Mar 2021 07:27:09 By Nasdaq GlobeNewswire

Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia

18 Feb 2021 07:53:31 By Nasdaq GlobeNewswire

Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021

11 Feb 2021 08:12:54 By Nasdaq GlobeNewswire

Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase

20 Jan 2021 06:00:00 By Nasdaq GlobeNewswire

Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

06 Jan 2021 06:00:01 By Nasdaq GlobeNewswire